1. Signaling Pathways
  2. MAPK/ERK Pathway
  3. p38 MAPK

p38 MAPK

The p38 MAPK family consists of highly conserved proline-directed serine-threonine protein kinases that are activated in response to a number many growth factors, cytokines, and chemotactic substances, such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), PDGF, TNF, interleukins, lipopolysaccharide (LPS) and formyl-methionyl-leucyl-phenylalanine (fMLP). It is well known that p38 is involved in inflammation, apoptosis, cardiomyocyte hypertrophy and cell differentiation.

The p38 MAPK family is composed of four proteins: p38α (encoded by the gene Mapk14), p38β (Mapk11), p38γ (Mapk12), and p38δ (Mapk13). Their coding genes have a distinct tissue distribution and they appear differentially expressed, being Mapk14 the most highly expressed. p38 MAPKs are substrates for three MAP2K (MKK6, MKK3, and MKK4). The contribution of each of these MAP2K to p38 MAPKs activation depends on the stimulus and the cell type. The MAP3Ks that lead to p38 MAPKs activation are ASK1, DLK1, TAK1, TAO1, TAO2, TPL2, MLK3, MEKK3, MEKK4, and ZAK1.

p38 MAPK Related Products (48):

Cat. No. Product Name Effect Purity
  • HY-10256
    SB 203580 Inhibitor 99.92%
    SB 203580 (RWJ 64809) is a widely used p38 MAPK inhibitor with an IC50 of 0.3-0.5 μM. SB 203580 (RWJ 64809) shows more than 100-fold selectivity over Akt (PKB), LCK, and GSK-3β.
  • HY-10295
    SB 202190 Inhibitor 99.89%
    SB 202190 is a cell-permeable p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38 and p38β2, respectively.
  • HY-10320
    Doramapimod Inhibitor 99.72%
    Doramapimod (BIRB 796) is a highly potent p38 MAPK inhibitor with an IC50 of 4 nM. It also inhibits B-Raf with an IC50 of 83 nM.
  • HY-13241
    Ralimetinib dimesylate Inhibitor 99.98%
    Ralimetinib dimesylate (LY2228820 dimesylate) is a selective, ATP-competitive inhibitor of p38 MAPK α/β with IC50s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38a MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc.
  • HY-11068
    SB 239063 Inhibitor 99.53%
    SB 239063 is a potent and selective p38 MAPK inhibitor (IC50 = 44 nM for p38α).
  • HY-114423
    p38α inhibitor 1 Inhibitor 98.70%
    p38α inhibitor 1 is a p38α inhibitor extracted from patent WO 2008076265 A1.
  • HY-P0117A
    Tat-NR2B9c TFA Inhibitor 98.99%
    Tat-NR2B9c (TFA) is a 20-aa peptide, which acts as a postsynaptic density-95 (PSD-95) inhibitor, with an EC50 of 6.7 nM for PSD-95d2 (PSD-95 PDZ domain 2), and 670 nM for PSD-95d1. Tat-NR2B9c also reduces NMDA-induced p38 activation, and possesses neuroprotective efficacy.
  • HY-W018643
    Ferulic acid methyl ester Inhibitor 99.18%
    Ferulic acid methyl ester (Methyl ferulate) is a derivative of ferulic acid, isolated from Stemona tuberosa, with anti-inflammatory and antioxidant properties. Ferulic acid methyl ester is a cell membrane and brain permeable compound, shows free radical scavenging ability, used in the research of neurodegenerative disorders. Ferulic acid methyl ester inhibits COX-2 expression, blocks p-p38 and p-JNK in primary bone marrow derived-macrophages.
  • HY-10256A
    SB 203580 hydrochloride Inhibitor 99.71%
    SB 203580 hydrochloride (RWJ 64809 hydrochloride) is a widely used p38 MAPK inhibitor with an IC50 of 0.3-0.5 μM. SB 203580 hydrochloride shows more than 100-fold selectivity over Akt (PKB), LCK, and GSK-3β.
  • HY-10402
    Losmapimod Inhibitor
    Losmapimod is a selective, potent, and orally active p38 MAPK inhibitor with pKis of 8.1 and 7.6 for p38α and p38β, respectively.
  • HY-N0674A
    Dehydrocorydaline chloride Activator 99.95%
    Dehydrocorydaline chloride is an alkaloidal that has anti-inflammatory and anti-cancer activities. Dehydrocorydaline chloride can elevate p38 MAPK activation.
  • HY-10578
    PD 169316 Inhibitor 98.33%
    PD 169316 is a potent, cell-permeable and selective p38 MAP kinase inhibitor, with IC50 of 89 nM.
  • HY-10456
    TAK-715 Inhibitor 99.93%
    TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1.
  • HY-10406
    Talmapimod Inhibitor 98.73%
    Talmapimod (SCIO-469) is a selective ATP-competitive p38 inhibitor with IC50 of 9 nM for p38α.
  • HY-P0117
    Tat-NR2B9c Inhibitor 98.22%
    Tat-NR2B9c is a 20-aa peptide, which acts as a postsynaptic density-95 (PSD-95) inhibitor, with an EC50 of 6.7 nM for PSD-95d2 (PSD-95 PDZ domain 2), and 670 nM for PSD-95d1; Tat-NR2B9c also reduces NMDA-induced p38 activation, and possesses neuroprotective efficacy.
  • HY-10401
    VX-702 Inhibitor 99.75%
    VX-702 is a highly selective inhibitor of p38α MAPK(IC50=4 -20 nM), 14-fold higher potency against the p38α versus p38β.
  • HY-10403
    PH-797804 Inhibitor 98.59%
    PH-797804 is a novel pyridinone inhibitor of p38α with IC50 of 26 nM; 4-fold more selective versus p38β and does not inhibit JNK2.
  • HY-100114
    TA-01 Inhibitor 99.93%
    TA-01 is a potent CK1 and p38 MAPK inhibitor, with IC50s of 6.4 nM, 6.8 nM, 6.7 nM for CK1ε, CK1δ and p38 MAPK, respectively.
  • HY-12511
    SKF-86002 Inhibitor 99.51%
    SKF-86002 is a potent inhibitor of p38 MAP kinase wit IC50 of 0.5-1 uM; inhibits LPS-induced IL-1 and TNF-α production in human monocytes (IC50 = 1 μM).
  • HY-16715
    Acumapimod Inhibitor 99.14%
    Acumapimod (BCT197) is an orally active p38 MAP kinase inhibitor, with an IC50 of less than 1 μM for p38α.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.